Test Price
2,800 AED✅ Home Collection Available
FGF23 Gene, Autosomal Dominant Hypophosphatemic Rickets – Genetic Test in UAE
Executive Summary & Core Metrics
This advanced genetic test delivers definitive diagnosis of autosomal dominant hypophosphatemic rickets (ADHR) through targeted NGS of the FGF23 gene, enabling precise clinical management and family risk assessment. Our ISO‑certified laboratory combines 99.9% diagnostic sensitivity with full UAE regulatory compliance, including VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection and post‑test genetic counselling.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Paid Hospital‑Grade Home Collection via VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection.
Clinical Guidance: Telephonic Post‑Test Clinical Guidance for result interpretation by a DHA‑licensed genetic counsellor.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FGF23 Next‑Generation Sequencing (NGS) test analyses the entire coding region of the FGF23 gene to detect pathogenic variants responsible for autosomal dominant hypophosphatemic rickets. This rare disorder causes renal phosphate wasting, leading to rickets, bone pain, and growth retardation. Our test offers a definitive molecular diagnosis, distinguishing ADHR from other hypophosphatemic conditions, and supports accurate genetic counselling.
| Feature | Our Test – FGF23 NGS | Closest Alternative – Whole Exome Sequencing |
|---|---|---|
| Precision | Targeted deep coverage (>100×) for FGF23; includes splice‑site analysis | Broad coverage, variable depth; may require additional Sanger confirmation |
| Methodology | NGS with Sanger validation of all detected variants | NGS only; validation performed only for selected variants |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Clinical Report | ACMG‑compliant interpretation, family risk assessment, and genetic counselling note | Generic report with secondary findings; often requires re‑analysis by a specialist |
| Price (AED) | 2800 | 5500–7200 |
| DHA Accreditation | Yes | Varies by provider |
Physician Insight & Safety Protocols
"As a clinical geneticist, I want families to understand that this test is not a standalone screening tool; it must be interpreted alongside serum phosphate, FGF23 levels, and renal tubular function. A positive result confirms ADHR and allows targeted therapy and informed reproductive choices, but clinical outcomes depend on early intervention and lifelong monitoring. My team and I ensure that every report is accompanied by a thorough post‑test counselling session to address your concerns."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠ Do not discontinue prescribed phosphate supplements, active vitamin D, or calcitriol without consulting your physician. The test result guides therapy adjustment but does not replace ongoing medical care.
Safety Exclusion Criteria & Red Flags
- Exclusion: Active fever (>38.5°C), recent blood transfusion (within 4 weeks), or inability to provide informed consent (guardian required for minors).
- Home Collection Refusal: If the patient is unable to maintain stable venous access or has a history of severe needle phobia, phlebotomy may be rescheduled at a clinical facility.
- Red Flags – Seek Immediate ER Care: Acute bone pain with swelling or deformity, inability to bear weight, new‑onset seizures (hypocalcemia), or severe muscle weakness – these may indicate metabolic decompensation unrelated to the gene test result.
Patient FAQ & Clinical Guidance
1. What is the FGF23 gene test and why is it recommended?
The FGF23 gene test is a targeted next‑generation sequencing assay that detects mutations in the FGF23 gene responsible for autosomal dominant hypophosphatemic rickets, enabling a definitive diagnosis and guiding lifelong phosphate management and genetic counselling. In the UAE, it is particularly valuable for families with a history of early‑onset rickets or unexplained bone deformities, as it differentiates ADHR from other hereditary hypophosphatemias and avoids unnecessary vitamin D toxicity.
2. How is the sample collected and how long do results take?
A single drop of blood on an FTA card, extracted DNA, or 3 mL of whole blood in an EDTA tube is collected via our VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection service. Results are available within 3 to 4 weeks through a secure patient portal with optional telephonic interpretation by our Consultant Medical Genetics.
3. Is this test covered by UAE health insurance, and are minors eligible?
Coverage varies by policy, but many UAE insurers now reimburse targeted genetic testing when pre‑authorised. Minors can be tested with mandatory parental consent under the Federal Decree‑Law No. 4 of 2016 on Medical Liability after an in‑person genetic counselling session. Our team assists with direct billing verification and provides the required pre‑authorisation forms, ensuring full compliance with all applicable regulations.
4. What happens after I receive a positive result?
A positive result confirms the diagnosis of autosomal dominant hypophosphatemic rickets. Your report includes ACMG‑compliant interpretation, family risk assessment, and a dedicated genetic counselling session. Our Consultant Medical Genetics will guide you through treatment options, including phosphate supplementation and active vitamin D therapy, and coordinate with your primary physician for ongoing management.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Statement
DNA Labs UAE operates under Dubai Healthcare City (DHCC) and Dubai Health Authority (DHA) regulations. All genetic testing procedures strictly comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient safety and clinical governance are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, access‑controlled, and never shared with third parties without explicit consent.
Clinical & Logistical Metadata
| Test Name | FGF23 Gene, Autosomal Dominant Hypophosphatemic Rickets – Genetic Test (NGS) |
| Price (AED) | 2800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), FTA Card, or Extracted DNA |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger Validation |
| ICD-10-CM Code | E83.31 |
| LOINC Code | 91653-5 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians